|Bid||211.15 x 1200|
|Ask||226.79 x 900|
|Day's range||221.14 - 224.73|
|52-week range||180.93 - 348.67|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||213.37|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the first patient enrolled in STORM-PE, a first-of-its-kind prospective, multi-center, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus Lightning Flash™ for the treatment of pulmonary embolism (PE). In partnership with PERT Consortium™, a multi-disciplinary group dedicated to improving the care of patients with PE, the STORM-PE trial aims to advance the understan
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.
Everyday, memories of the people who served in World War II, Vietnam, and the Korean War are disappearing from living history. Virtual reality companies from around the world have teamed up in a program called "Honor Everywhere" to ensure the memorials are still accessible to these aging and terminally ill men and women via immersive stories.